Every action in clinical development is born from a deep commitment to people
Business
Responsible innovation to transform lives
At Ferrer we promote responsible innovation aimed at improving the lives of people with unmet medical needs. This commitment is part of our purpose – to use business to fight for social justice – and guides an R+D strategy aligned with European health priorities and the Sustainable Development Goals.
R&D Strategy
At Ferrer we focus our efforts on highly complex rare diseases, especially neurological diseases and pulmonary vascular and interstitial lung diseases, where there is a high burden on patients and an urgent need for new therapeutic solutions.
Our approach to R&D is comprehensive and oriented towards making a real impact on people's lives:
We transform scientific knowledge into solutions that generate a tangible impact on people's lives, thereby contributing to a fairer society
We integrate the perspective of patients, healthcare professionals and health systems from the early stages of development, incorporating areas such as Patient Advocacy, Medical Affairs and Market Access to ensure that each scientific decision responds to real needs. This approach is supported by an integrated end-to-end model that covers the entire value chain, from research and development to manufacturing and marketing, allowing us to move forward in a coordinated, agile way and with high quality standards.
At the same time, we combine our internal capabilities with external collaborations to enhance innovation and accelerate the development of therapeutic solutions in highly complex areas. This commitment is reinforced through continuous improvement and life-cycle management initiatives, aimed at optimising our products and incorporating more sustainable solutions adapted to the needs of patients.
Discover our lines of innovation and development
-
Pipeline
We have a pipeline under development focused on addressing unmet medical needs, with innovative therapies aimed at significantly improving patients' quality of life. -
Clinical research
We drive expanded access programs to facilitate early availability of investigational treatments, enabling patients with limited options to benefit from innovative therapies. -
Managed Access Programs
Managed Access Programs complement standard pathways to treatment access when needed by patients.